Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
0.295
-0.019 (-6.05%)
At close: Feb 21, 2025, 4:00 PM
0.300
+0.005 (1.69%)
After-hours: Feb 21, 2025, 7:13 PM EST
Relmada Therapeutics Employees
Relmada Therapeutics had 20 employees as of December 31, 2023. The number of employees increased by 6 or 42.86% compared to the previous year.
Employees
20
Change (1Y)
6
Growth (1Y)
42.86%
Revenue / Employee
n/a
Profits / Employee
-$4,324,369
Market Cap
8.90M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
RLMD News
- 16 days ago - Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB - GlobeNewsWire
- 2 months ago - Relmada discontinues late-stage trials for depression drug, explores sale - Reuters
- 2 months ago - Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017 - GlobeNewsWire
- 2 months ago - Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why - Benzinga
- 2 months ago - Relmada's depression drug unlikely to meet main trial goal, analysis shows - Reuters
- 2 months ago - Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance - GlobeNewsWire
- 3 months ago - Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm - GlobeNewsWire
- 3 months ago - Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease - GlobeNewsWire